ArticleScientific reports2025
Galantamine-loaded PLGA nanoparticles reduce oxidative stress and inflammation in a rat model of spinal cord injury.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tissue engineering for traumatic spinal cord injury: Research advances and clinical translation.Bioactive materials · 2026Review
- Th17 cells and IL-17A in traumatic brain injury: mechanisms and therapeutic perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) represents a debilitating condition with no effective treatments currently available. Previous research demonstrated that galantamine improves functional outcomes in SCI models. However, systemic administration results in limited target tissue bioavailability. This study aimed to develop and evaluate the therapeutic potential of galantamine-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles for SCI treatment. Galantamine-containing PLGA particles (PG) were synthesized via electrospraying, yielding nanoparticles with 568 nm average diameter, - 23 mV zeta potential, 12.87% encapsulation efficiency, and drug release over 35 days. In a rat contusion SCI model, animals received direct implantation of galantamine alone, empty PLGA particles, or PG. Locomotor assessment over 6 weeks revealed significant functional improvements only in the PG group. Tissue analysis at 3 days and 6 weeks post-injury showed that PG treatment significantly reduced oxidative stress markers as ROS production and lipid peroxidation, and selectively reduced IL-1β but did not significantly affect IL-6 levels. Flow cytometry analysis revealed reduced GFAP expression in PLGA and PG-treated groups, indicating decreased astrocyte activation, while neuronal markers (neurofilament-M, βIII-tubulin) and oligodendrocyte markers (O4) showed no significant changes between groups. These results demonstrate that galantamine-loaded PLGA nanoparticles provide superior therapeutic outcomes through targeted anti-inflammatory, antioxidant, and glial modulation mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.